Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04833855 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 183
- Enrollment target
NCT04833855 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 183 participants.
The verdict
NCT04833855, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 183 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the effect of tezepelumab on improvement in the Urticaria Activity Score over 7 days (UAS7).
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Omalizumab
- BIOLOGICAL Tezepelumab Dose 1
- BIOLOGICAL Tezepelumab Dose 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 183 participants |
| Start Date | 2021-04-15 |
| Est. Completion | 2023-04-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04833855
The ClinicalTrials.gov registry entry for NCT04833855 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 183 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT04833855 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04833855 about?
NCT04833855 is a clinical study titled "Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria". The primary objective of this study is to evaluate the effect of tezepelumab on improvement in the Urticaria Activity Score over 7 days (UAS7).
What is the current status of trial NCT04833855?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 183 participants. The study started on 2021-04-15. Estimated completion is 2023-04-13.
What interventions are being tested in trial NCT04833855?
The interventions under investigation include: Placebo (BIOLOGICAL), Omalizumab (BIOLOGICAL), Tezepelumab Dose 1 (BIOLOGICAL), Tezepelumab Dose 2 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04833855?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.